Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors.

Ponomarenko DM, Klimova ID, Chapygina YA, Dvornichenko VV, Zhukova NV, Orlova RV, Manikhas GM, Zyryanov AV, Burkhanova LA, Badrtdinova II, Oshchepkov BN, Filippova EV, Orlov SV, Kolesnikov SI, Sufianov AA, Baum SR, Zaitzeva OY, Komissarov AB, Grudinin MP, Kiselev OI, Tsyb AF, Venanzi F, Shcherbinina V, Chursov A, Gabai VL, Shneider AM.

Oncotarget. 2017 Mar 25;8(32):53730-53739. doi: 10.18632/oncotarget.16574. eCollection 2017 Aug 8.

2.

[Adenosine A2A receptor as a drug target for treatment of sepsis].

Sivak KV, Vasin AV, Egorov VV, Tsevtkov VB, Kuzmich NN, Savina VA, Kiselev OI.

Mol Biol (Mosk). 2016 Mar-Apr;50(2):231-45. doi: 10.7868/S0026898416020233. Review. Russian.

3.

The influenza A virus NS genome segment displays lineage-specific patterns in predicted RNA secondary structure.

Vasin AV, Petrova AV, Egorov VV, Plotnikova MA, Klotchenko SA, Karpenko MN, Kiselev OI.

BMC Res Notes. 2016 May 20;9:279. doi: 10.1186/s13104-016-2083-6.

4.

[ANTIVIRAL ACTIVITY OF THE DIHYDROQUERCETIN DURING THE COXSACKIEVIRUS B4 REPLICATION IN VITRO].

Galochkina AV, Zarubaev VV, Kiselev OI, Babkin VA, Ostroukhova LA.

Vopr Virusol. 2016;61(1):27-31. Russian.

PMID:
27145597
5.

[Oncolytic potential of recombinant influenza A virus vectors on a model of malignant glioma in vivo].

Shurygina APS, Kartashev AV, Kovanko EG, Kiseleva LN, Pustovalov YI, Slita AK, Zarubaev VV, Belyaevskaya SV, Sirotkin AK, Kiselev OI, Egorov AY.

Vopr Onkol. 2016;62(1):138-45. Russian.

PMID:
30444592
6.

CHRONIC HEPATITIS WITH DOUBLE B/C INFECTION: VIROLOGICAL, CLINICAL, MORPHOLOGICAL CHARACTERISTICS.

Dudanova OP, Shubina ME, Belavina IA, Elpaeva EA, Pisareva MM, Grudinin MP, Kiselev OI.

Klin Med (Mosk). 2016;94(4):289-294.

PMID:
28957609
7.

Discovery of a new class of antiviral compounds: camphor imine derivatives.

Sokolova AS, Yarovaya OI, Shernyukov AV, Gatilov YV, Razumova YV, Zarubaev VV, Tretiak TS, Pokrovsky AG, Kiselev OI, Salakhutdinov NF.

Eur J Med Chem. 2015 Nov 13;105:263-73. doi: 10.1016/j.ejmech.2015.10.010. Epub 2015 Oct 22.

PMID:
26498572
8.

[Ebola hemorrhagic fever: Properties of the pathogen and development of vaccines and chemotherapeutic agents].

Kiselev OI, Vasin AV, Shevyryova MP, Deeva EG, Sivak KV, Egorov VV, Tsvetkov VB, Egorov AY, Romanovskaya-Romanko EA, Stepanova LA, Komissarov AB, Tsybalova LM, Ignatjev GM.

Mol Biol (Mosk). 2015 Jul-Aug;49(4):541-54. doi: 10.7868/S0026898415040072. Russian.

9.

[Comparison of the influenza epidemics in Russia caused by the pandemic virus A(H1N1)pdm09 within the period from 2009 to 2013].

Karpova LS, Sominina AA, Burtseva EI, Pelikh MY, Feodoritova EL, Popovtseva NM, Stolyarov TP, Kiselev OI.

Vopr Virusol. 2015;60(3):19-24. Russian.

PMID:
26281302
10.

Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.

Tsybalova LM, Stepanova LA, Kuprianov VV, Blokhina EA, Potapchuk MV, Korotkov AV, Gorshkov AN, Kasyanenko MA, Ravin NV, Kiselev OI.

Vaccine. 2015 Jun 26;33(29):3398-406. doi: 10.1016/j.vaccine.2015.04.073. Epub 2015 May 11.

PMID:
25976545
11.

[Clinical efficacy of arbidol (umifenovir) in the therapy of influenza in adults: preliminary results of the multicenter double-blind randomized placebo-controlled study ARBITR].

Kiselev OI, Maleev VV, Deeva EG, Leneva IA, Selkova EP, Osipova EA, Obukhov AA, Nadorov SA, Kulikova EV.

Ter Arkh. 2015;87(1):88-96. doi: 10.17116/terarkh201587188-96. Russian.

PMID:
25823275
12.

Glycyrrhizic acid derivatives as influenza A/H1N1 virus inhibitors.

Baltina LA, Zarubaev VV, Baltina LA, Orshanskaya IA, Fairushina AI, Kiselev OI, Yunusov MS.

Bioorg Med Chem Lett. 2015 Apr 15;25(8):1742-1746. doi: 10.1016/j.bmcl.2015.02.074. Epub 2015 Mar 7.

PMID:
25801933
13.

Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.

Stepanova LA, Kotlyarov RY, Kovaleva AA, Potapchuk MV, Korotkov AV, Sergeeva MV, Kasianenko MA, Kuprianov VV, Ravin NV, Tsybalova LM, Skryabin KG, Kiselev OI.

PLoS One. 2015 Mar 23;10(3):e0119520. doi: 10.1371/journal.pone.0119520. eCollection 2015.

14.

Identification of genetic determinants of influenza A virus resistance to adamantanes and neuraminidase inhibitors using biological microarray.

Heydarov RN, Fesenko EE, Shaskolskiy BL, Klotchenko SA, Vasin AV, Titov SV, Dementieva EI, Zasedatelev AS, Mikhailovich VM, Kiselev OI.

Dokl Biochem Biophys. 2015;460:4-8. doi: 10.1134/S1607672915010032. Epub 2015 Mar 13. No abstract available.

PMID:
25772979
15.

[The use of apoptosis inducers in the therapy of experimental influenza infection and preventing of chronic post-influenza lung damage].

Zarubaev VV, Tribulovich VG, Beliavskaia SV, Barlev NA, Kiselev OI.

Tsitologiia. 2014;56(3):241-7. Russian.

PMID:
25509421
16.

Novel derivatives of usnic acid effectively inhibiting reproduction of influenza A virus.

Shtro AA, Zarubaev VV, Luzina OA, Sokolov DN, Kiselev OI, Salakhutdinov NF.

Bioorg Med Chem. 2014 Dec 15;22(24):6826-36. doi: 10.1016/j.bmc.2014.10.033. Epub 2014 Oct 31.

PMID:
25464881
17.

Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.

Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.

Antiviral Res. 2015 Jan;113:4-10. doi: 10.1016/j.antiviral.2014.10.015. Epub 2014 Nov 12.

PMID:
25446335
18.

Molecular mechanisms enhancing the proteome of influenza A viruses: an overview of recently discovered proteins.

Vasin AV, Temkina OA, Egorov VV, Klotchenko SA, Plotnikova MA, Kiselev OI.

Virus Res. 2014 Jun 24;185:53-63. doi: 10.1016/j.virusres.2014.03.015. Epub 2014 Mar 24. Review.

PMID:
24675275
19.

[Universal diagnostic oligonucleotide microarray for subtyping of human and animal influenza A viruses].

Vasin AV, Sandybaev NT, Plotnikova MA, Klotchenko SA, Cherviakova OV, Strochkov VM, Taĭlakova ÉT, Temkina OA, Brodskaia AV, Zabrodskaia IaA, Nikulenkov KP, Egorov VV, Koshemetov ZhK, Sancyzbaĭ AR, Kiselev OI.

Vopr Virusol. 2013 Sep-Oct;58(5):32-7. Russian.

PMID:
24640169
20.

Camphor-based symmetric diimines as inhibitors of influenza virus reproduction.

Sokolova AS, Yarovaya OC, Korchagina DV, Zarubaev VV, Tretiak TS, Anfimov PM, Kiselev OI, Salakhutdinov NF.

Bioorg Med Chem. 2014 Apr 1;22(7):2141-8. doi: 10.1016/j.bmc.2014.02.038. Epub 2014 Mar 1.

PMID:
24631360
21.

Structural Features of the Peptide Homologous to 6-25 Fragment of Influenza A PB1 Protein.

Egorov VV, Matusevich OV, Shaldzhyan AA, Skvortsov AN, Zabrodskaya YA, Garmay YP, Landa SB, Lebedev DV, Zarubayev VV, Sirotkin AK, Vasin AV, Kiselev OI.

Int J Pept. 2013;2013:370832. doi: 10.1155/2013/370832. Epub 2013 Dec 24.

22.

[Intranasal co-administration of recombinant streptococcus group B polypeptides and influenza deltaNS1 vaccine].

Shurygina AP, Leont'eva GF, Grabovskaia KB, Gupalova TV, Koroleva IV, Kramskaia TA, Kiselev OI, Egorov AIu, Suvorov AN.

Vopr Virusol. 2013 May-Jun;58(3):28-31. Russian.

PMID:
24006630
23.

New quaternary ammonium camphor derivatives and their antiviral activity, genotoxic effects and cytotoxicity.

Sokolova AS, Yarovaya CO, Shernyukov CA, Pokrovsky CE, Pokrovsky CA, Lavrinenko VA, Zarubaev VV, Tretiak TS, Anfimov PM, Kiselev OI, Beklemishev AB, Salakhutdinov NF.

Bioorg Med Chem. 2013 Nov 1;21(21):6690-8. doi: 10.1016/j.bmc.2013.08.014. Epub 2013 Aug 12.

PMID:
23993669
24.

An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A/Chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans.

Sansyzbay AR, Erofeeva MK, Khairullin BM, Sandybayev NT, Kydyrbayev ZK, Mamadaliyev SM, Kassenov MM, Sergeeva MV, Romanova JR, Krivitskaya VZ, Kiselev OI, Stukova MA.

Clin Vaccine Immunol. 2013 Aug;20(8):1314-9. doi: 10.1128/CVI.00096-13. Epub 2013 Jun 26.

25.

[Genetic diversity and molecular evolution of the influenza A viruses in Russia during 2006-2012].

Grudinin MP, Komissarov AB, Pisareva MM, Stukova MA, Buzitskaia ZhV, Paiankova AA, Elpaeva EA, Zadonskaia AV, Ivanov IuV, Kiselev OI.

Vopr Virusol. 2012 Nov-Dec;57(6):37-42. Russian.

PMID:
23477253
26.

[Development of novel drugs against influenza virus based on synthetic and natural compounds].

Zarubaev VV, Anfimov PM, Shtro AA, Garshinina AV, Meleshkina IA, Karpinskaia LA, Kozeletskaia KN, Kiselev OI.

Vopr Virusol. 2012 Nov-Dec;57(6):30-6. Russian.

PMID:
23477252
27.

[Characterization of cold-adapted influenza strain A/HongKong/1/68/162/35 as a potential donor of attenuation and high reproduction].

Tsybalova LM, Gorev NE, Potapchuk MV, Repko IA, Korotkov AV, Sergeeva MV, Komissarov AB, Pisareva MM, Kuznetsov VV, Grudinin MP, Kiselev OI.

Vopr Virusol. 2012 Nov-Dec;57(6):13-7. Russian.

PMID:
23477248
28.

[A new antiviral drug Triazavirin: results of phase II clinical trial].

Kiselev OI, Deeva EG, Mel'nikova TI, Kozeletskaia KN, Kiselev AS, Rusinov VL, Charushin VN, Chupakhin ON.

Vopr Virusol. 2012 Nov-Dec;57(6):9-12. Russian.

PMID:
23477247
29.

[Immunosuppression at pregnancy and flu].

Kiselev OI.

Vopr Virusol. 2012 Nov-Dec;57(6):5-8. Review. Russian.

PMID:
23477246
30.

Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco mosaic virus-based vectors.

Petukhova NV, Gasanova TV, Stepanova LA, Rusova OA, Potapchuk MV, Korotkov AV, Skurat EV, Tsybalova LM, Kiselev OI, Ivanov PA, Atabekov JG.

Curr Pharm Des. 2013;19(31):5587-600.

PMID:
23394564
31.

The use of transient expression systems for the rapid production of virus-like particles in plants.

Thuenemann EC, Lenzi P, Love AJ, Taliansky M, Bécares M, Zuñiga S, Enjuanes L, Zahmanova GG, Minkov IN, Matić S, Noris E, Meyers A, Hattingh A, Rybicki EP, Kiselev OI, Ravin NV, Eldarov MA, Skryabin KG, Lomonossoff GP.

Curr Pharm Des. 2013;19(31):5564-73. Review.

PMID:
23394559
32.

Recombinant influenza vaccines.

Sedova ES, Shcherbinin DN, Migunov AI, Smirnov IuA, Logunov DIu, Shmarov MM, Tsybalova LM, Naroditskiĭ BS, Kiselev OI, Gintsburg AL.

Acta Naturae. 2012 Oct;4(4):17-27.

33.

Transmission studies resume for avian flu.

Fouchier RA, García-Sastre A, Kawaoka Y, Barclay WS, Bouvier NM, Brown IH, Capua I, Chen H, Compans RW, Couch RB, Cox NJ, Doherty PC, Donis RO, Feldmann H, Guan Y, Katz JM, Kiselev OI, Klenk HD, Kobinger G, Liu J, Liu X, Lowen A, Mettenleiter TC, Osterhaus AD, Palese P, Peiris JS, Perez DR, Richt JA, Schultz-Cherry S, Steel J, Subbarao K, Swayne DE, Takimoto T, Tashiro M, Taubenberger JK, Thomas PG, Tripp RA, Tumpey TM, Webby RJ, Webster RG.

Science. 2013 Feb 1;339(6119):520-1. doi: 10.1126/science.1235140. Epub 2013 Jan 23. No abstract available.

34.

[Deitiforine, an antiinfluenza chemotherapeutic].

Tandura SN, Zarubaev VV, Anfimov PM, Kiselev OI.

Antibiot Khimioter. 2013;58(1-2):36-48. Review. Russian.

PMID:
24640143
35.

[Technological approaches to development of whole-virion inactivated vaccine from recombinant strain against A/H5N1 influenza in the Republic of Kazakhstan].

Kydyrbaev ZhK, Mamadaliev SM, Asanzhanova NN, Tabynov KK, Ryskel'dinova ShZh, Cherviakova OV, Sandybaev NT, Khaĭrullin BM, Kiselev OI.

Zh Mikrobiol Epidemiol Immunobiol. 2012 Sep-Oct;(5):54-9. Russian.

PMID:
23163037
36.

[Molecular-biological properties of the rubella virus strains isolated in St. Petersburg].

Buzitskaia ZhV, Sirotkin AK, Gudkova TM, Prochukhanova AP, Karpov AV, Tsybalova LM, Kiselev OI.

Mol Biol (Mosk). 2012 Jul-Aug;46(4):672-6. Russian.

PMID:
23113357
37.

Anti-viral activity of (-)- and (+)-usnic acids and their derivatives against influenza virus A(H1N1)2009.

Sokolov DN, Zarubaev VV, Shtro AA, Polovinka MP, Luzina OA, Komarova NI, Salakhutdinov NF, Kiselev OI.

Bioorg Med Chem Lett. 2012 Dec 1;22(23):7060-4. doi: 10.1016/j.bmcl.2012.09.084. Epub 2012 Oct 4.

PMID:
23099095
38.

A molecular assembly system for presentation of antigens on the surface of HBc virus-like particles.

Blokhina EA, Kuprianov VV, Stepanova LA, Tsybalova LM, Kiselev OI, Ravin NV, Skryabin KG.

Virology. 2013 Jan 20;435(2):293-300. doi: 10.1016/j.virol.2012.09.014. Epub 2012 Oct 11.

39.

[Effect of Ingavirin on the ultrastructure of the morphogenesis of adenovirus infection in vivo].

Zarubaev VV, Slita AV, Sirotkin AK, Beliavskaia SV, Nebol'sin VE, Reĭkhart DV, Kiselev OI.

Vopr Virusol. 2012 May-Jun;57(3):17-23. Russian.

PMID:
22905422
40.

[Effect of different water-soluble forms of the fullerene C60 on the metabolic activity and ultra-structure of cells in culture].

Eropkina EM, Il'inskaia EV, Litasova EV, Eropkin MIu, Piotrovskiĭ LB, Dumpis MA, Kiselev OI.

Biofizika. 2012 May-Jun;57(3):468-75. Russian.

PMID:
22873071
41.

[Ingavirin treatment of experimental parainfluenza pneumonia in Syrian hamsters].

Zarubaev VV, Garshinina AV, Kalinina NA, Beliaevskaia SV, Nebol'sin VE, Kiselev OI, Reĭkhart DV.

Vopr Virusol. 2012 Mar-Apr;57(2):35-9. Russian.

PMID:
22834146
42.

[Prognostic value of human papilloma virus DNA test in patients surgically treated for squamous cell cervical cancer].

Bakhidze EV, Lavrinovich OE, Chepik OF, Kiselev OI.

Vopr Onkol. 2012;58(2):233-7. Russian.

PMID:
22774530
43.

[Universal influenza vaccines: developments, prospects for use].

Tsybalova LM, Kiselev OI.

Vopr Virusol. 2012 Jan-Feb;57(1):9-14. Review. Russian.

PMID:
22624467
44.

[Antiviral activity of Ingavirin on an animal model for experimental disseminated adenovirus infection].

Zarubaev VV, Slita AV, Beliaevskaia SV, Nebol'sin VE, Kiselev OI, Reĭkhart DV.

Vopr Virusol. 2011 Nov-Dec;56(6):23-7. Russian.

PMID:
22359945
45.

[Preclinical studies of live intranasal H5N1 influenza vaccine with the deleted HS1 gene].

Romanovskaia-Roman'ko EA, Ferko B, Vyshemirskiĭ OI, Romanova IuR, Krenn B, Muster T, Grudinin MP, Lapin BA, Egorov AIu, Kiselev OI.

Vopr Virusol. 2011 Nov-Dec;56(6):19-22. Russian.

PMID:
22359944
46.
47.

Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein.

Ravin NV, Kotlyarov RY, Mardanova ES, Kuprianov VV, Migunov AI, Stepanova LA, Tsybalova LM, Kiselev OI, Skryabin KG.

Biochemistry (Mosc). 2012 Jan;77(1):33-40. doi: 10.1134/S000629791201004X.

PMID:
22339631
48.

[Prevention of tuberculosis: current approaches to development of vaccines].

Stukova MA, Zabolotnykh NV, Vinogradova TI, Gergert VIa, Apt AS, Kaprel'iants AS, Erokhin VV, Iablonskiĭ PK, Kiselev OI.

Vestn Ross Akad Med Nauk. 2012;(11):45-52. Review. Russian.

PMID:
23457981
49.

[In vitro and in vivo effects of ingavirin on the ultrastructure and infectivity of influenza virus].

Zarubaev VV, Beliaevskaia SV, Sirotkin AK, Anfimov PM, Nebol'sin VE, Kiselev OI, Reĭkhart DV.

Vopr Virusol. 2011 Sep-Oct;56(5):21-5. Russian.

PMID:
22171473
50.

Activity of Ingavirin (6-[2-(1H-Imidazol-4-yl)ethylamino]-5-oxo-hexanoic Acid) Against Human Respiratory Viruses in in Vivo Experiments.

Zarubaev VV, Garshinina AV, Kalinina NA, Shtro AA, Belyaevskaya SV, Slita AV, Nebolsin VE, Kiselev OI.

Pharmaceuticals (Basel). 2011 Nov 25;4(12):1518-1534.

Supplemental Content

Loading ...
Support Center